CN EN

Products

Provide you with the best solution for the use of raw materials

Cardiac Markers Tumor Markers Inflammation Markers Thyroid Bone Metabolism Kidney Markers Preeclampsia Hormones Gastrointestinal Diseases Coagulation and Thrombosis Diabetes & Metabolism Alzheimer's Disease TORCH Infectious Diseases Drug of Abuse Veterinary Autoimmune Diseases Flow Cytometry Antibody General Reagents & Consumable

Preeclampsia (PE) is a serious and common pregnancy complication, which refers to the clinical occurrence of edema, hypertension, proteinuria, headache, dizziness, vomiting, epigastric discomfort, and visual disturbance after 24 weeks of pregnancy. Or symptoms such as blood pressure and systolic blood pressure above 160 mm Hg (21.3 kPa). Some data show that about 3%-5% of pregnant women will develop pre-eclampsia. If treatment and intervention are not carried out in time, it may develop into pregnancy eclampsia, which is one of the four major causes of death in obstetrics, and will lead to maternal and fetal or neonatal death.

  • Placental Growth Factor (PlGF)

    Placental growth factor (PLGF) was first isolated and purified from a human placental cDNA library in 1991 by Maglione et al. PLGF is synthesized mainly by syncytial trophoblasts and binds to tyrosinase receptors located on trophoblasts and vascular endothelial cells, and is a protein with autocrine effects on trophoblast function and paracrine effects on vascular growth. PLGF has a unique regulatory effect on trophoblast and endothelial cells, and can promote neovascularization. PLGF levels in pregnant women can be used clinically to diagnose placental insufficiency and to predict, identify and monitor the treatment of preterm pre-eclampsia.

    Cat.No. Product Name Application-Platform Product Description
    HA131-2MB PlGF Antibody Capture-FIA Mouse Antibody
    HA131-2H PlGF Antibody Detection-CLIA Humanized Antibody
    HA131-1M PlGF Antibody Detection/Capture-FIA/CLIA Mouse Antibody
    HP131-1 PlGF Antigen Quality Control-FIA/CLIA CHO
  • Soluble Fms-Like Tyrosine Kinase Receptor 1 (sFlt-1)

    β-amyloid protein, with a molecular weight of about 4 kDa, is produced by the hydrolysis of β-amyloid precursor protein (APP), which is secreted by cells and has a strong neurotoxic effect after precipitation and accumulation in the cell matrix. β-amyloid-β (Aβ) is a peptide containing 39-43 amino acids produced by the hydrolysis of amyloid precursor protein (APP) by β- and γ-secretase. Aβ is a 39-43 amino acid peptide produced by the proteolysis of amyloid precursor protein (APP) by β- and γ-secretase. It can be produced by a variety of cells and circulates in blood, cerebrospinal fluid and interstitial fluid, mostly bound to chaperone protein molecules, with a few existing in the free state. It is the main cause of degeneration and death of neurons around the senile plaques in the brain of AD patients.

    Cat.No. Product Name Application-Platform Product Description
    HA132-7M sflt-1 Antibody Detection-FIA/CLIA Mouse Antibody
    HA132-8M sflt-1 Antibody Detection-FIA Mouse Antibody
    HA132-1MB sflt-1 Antibody Capture-FIA Mouse Antibody
    HA132-6M sflt-1 Antibody Detection/Capture-FIA/CLIA Mouse Antibody
目前在第1页, 共有1页, 共有2条记录 第一页 上一页 1 下一页 最后一页 跳转到